DAFTAR PUSTAKA

1.

Navas-Acien A, Sharrett AR, Silbergeld EK, et al. Arsenic Exposure and

Cardiovascular

Disease: A

Systematic

Review

of The

Epidemiologic

Evidence. Am J Epidemiol. 2005;162:1037-1049

2.

Verschuren J, Trompet S, Wessels J, et al. A Systematic Reviw on

Pharmacogenetics in Cardiovascular Disease: Is It Ready for Clinical
Application?. European Heart Journal. 2012;3:165-175

3.

Frostegard J. Immunity, Atherosclerosis and Cardiovascular Disease. BMC

Medicine. 2013;11:117

4.

World Health Organization. Cardiovascular Disease Fact Sheet. World Health

Organization, Geneva, Switzerland. 2011

5.

Alberts-Grill N, Denning TL, Rezvan A, Jo H. The Role of The Vascular

Dendritic Cell Network in Atherosclerosis. Am J Physiol Cell Physiol.
2013;305:C1-C21

6.

Kim S, Park J, Kim K, et al. The Protective Effect of Apamin on LPS/FatInduced

Atherosclerotic

Mice.

Evidence-Based

Complementary

and

Alternative Medicine. 2012;2012:1-10

7.

Habets K, Puijvelde G, Duivenvoorde LM, et al. Vaccination Using Oxidized

Low-Density Lipoprotein-Pulsed Dendritic Cells Reduces Atherosclerosis in
LDL Receptor-Deficient Mice. Cardiovascular Research. 2010;85:622-630

8.

Bos D, Rijk M, Geeraedts T, et al. Intracranial Carotid Artery Atherosclerosis:

Prevalence and Risk Factors in the General Population. Stroke. 2012;43:18781884

9.

Tuzcu EM, Kapadia SR, Tutar R, et al. High Prevalence of Coronary

Atherosclerosis in Asymptomatic Teenagers and Young Adults. Circulation.
2001;103:2705-2710

10. Tomkin GH, Owens D. LDL as a Cause of Atherosclerosis. The Open

Atherosclerosis & Thrombosis Journal. 2012;5:13-21
11. Ross R. Atherosclerosis An Inflammatory Disease. The New England
Journal of Medicine. 1999;340(2):115-126

12. Itabe H, Obama T, Kato R. The Dynamics of Oxidized LDL during

Atherogenesis. Journal of Lipids. 2011;1-9
13. Hansson GK. Inflammation, Atherosclerosis, and Coronary Artery Disease. N
Engl J Med. 2005;352:1685-95
14. Roche LD, Hernandez DA. New Alternatives for Atherosclerosis Treatment
Based on Immunomodulation. ISRN Vascular Medicine. 2012;1-6
15. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants
in 14 randomised trials of statins. Lancet. 2005;366:12671278
16. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a
meta-analysis of randomized controlled trials. JAMA. 1999;282:23402346
17. Kushner FG, Hand M, Smith SC, et al. 2009 focused updates: ACC/AHA
guidelines for the management of patients with ST-elevation myocardial
infarction (updating the 2004 guideline and 2007 focused update) and
ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating
the 2005 guideline and 2007 focused update): a report of the American College
of Cardiology Foundation/American Heart Association Task Force on Practice
Guidelines. Circulation. 2009;120:22712306
18. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial
infarction in patients presenting with persistent ST-segment elevation: the Task
Force on the Management of ST-Segment Elevation Acute Myocardial
Infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909
2945
19. Pollack CV Jr, Braunwald E. 2007 update to the ACC/AHA guidelines for the
management of patients with unstable angina and non-ST-segment elevation
myocardial infarction: implications for emergency department practice. Ann
Emerg Med. 2008;51:591606
20. Rapezzi C, Biagini E, Branzi A. Guidelines for the diagnosis and treatment of
non-ST-segment elevation acute coronary syndromes: the task force for the
diagnosis and

treatment of non-ST-segment elevation

acute

coronary

syndromes of the European Society of Cardiology. Eur Heart J. 2008;29:277

278
21. Shimokawa T, Smith WL. Prostaglandin endoperoxide synthase. The aspirin
acetylation region. J Biol Chem. 1992;267:1238712392
22. Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase
1: effects on response to aspirin. Clin Pharmacol Ther. 2003;73:122130
23. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated
with increased risk of recurrent atherothrombotic events in patients with acute
myocardial infarction. Circulation. 2004;109:31713175.
24. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW,
Huisman

MV.

Clopidogrel

nonresponsiveness

in

patients

undergoing

percutaneous coronary intervention with stenting: a systematic review and

meta-analysis. Am Heart J. 2007;154:221231
25. Nordmann AJ, Hengstler P, Leimenstoll BM, Harr T, Young J, Bucher HC.
Clinical Outcomes of Stents Versus Balloon Angioplasty In Non-Acute
Coronary Artery Disease. European Heart Journal. 2004;25:69-80
26. Serruys P, Jaeger P, Kiemeneij F, et al. A Comparison of Balloon-ExpandableStent Implantation with Balloon Angioplasty In Patients with Coronary Artery
Disease. The New England Journal of Medicine. 1994;331(8):489-495
27. Zhao J, Ching L, Kou YR, et al. Activation of TRPV1 Prevents OxLDLInduced Lipid Accumulation and TNF--Induced Inflamation in Macrophages:
Role of Liver X Receptor . Mediators of Inflammation. 2013;2013:1-14
28. Zhang LL, Liu DY, Ma LQ, et al. Activation of transient receptor potential
vanilloid type-1 channel prevents adipogenesis and obesity. Circ Res.
2007;100:10631070
29. Ma L, Zhong J, Zhao Z, et al. Activation of TRPV1 reduces vascular lipid
accumulation

and

attenuates

atherosclerosis.

Cardiovascular

Research.

2011;92:504-513
30. Sanatombi K, Sharma GJ. Capsaicin Content and Pungency of Different
Capsicum spp. Cultivars. Not Bot Hort Agrobot Cluj. 2008;36(2):89-90

31. Bode AM, Dong Z. The Two Faces of Capsaicin. Cancer Res. 2011;71:28092814
32. Han SS, Keum YS, Seo HJ, Chun KS, Lee SS, Surh YJ. Capsaicin suppresses
phorbol ester-induced activation of NF-kappaB/Rel and AP-1 transcription
factors in mouse epidermis. Cancer Lett. 2001. 164(2):119-26.
33. Seong-Su Han, Young-Sam Keum, Kyung-Soo Chun, Young-Joon Surh.
Suppression of phorbol ester-induced NF-B activation by capsaicin in
cultured human promyelocytic leukemia cells. Archives of

Pharmacal

Research. Volume 25. Issue 4. 2002. pp 475-479.

34. D. J. Preiss, N. Sattar. Vascular cell adhesion molecule-1: a viable therapeutic
target for atherosclerosis? Int J Clin Pract. 2007. pp 697701.
35. Kathryn J. Moore, Ira Tabas.

Macrophages in the Pathogenesis of

Atherosclerosis. Cell 145. 2011. pp 1-5

36. Becker, L., Gharib, S.A., Irwin, A.D., Wijsman, E., Vaisar, T., Oram, J.F., and
Heinecke,

J.W.

macrophage

sterol-responsive

network

linked

to

atherogenesis. Cell Metab. Vol 11. 2010. pp 125135.

37. Iyer AK, Greish K, Seki T, Okazaki S, Fang J, Takeshita K, Maeda H,
Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based
on EPR effect and singlet oxygen generation. J Drug Target. 2007. 15: 496
506.
38. Wang L, Bao Y, Yang Y, Wu Y, Chen X, Si S, Hong B. Discovery of
Antagonists for Human Scavenger Receptor CD36 via an ELISA-Like HighThroughput Screening Assay. J Biomol Screen. 2010; 15(3):239250.
39. Schrijvers DM, De Meyer GR, Herman AG, Martinet W. Phagocytosis in
atherosclerosis:

Molecular

mechanisms

and

implications

for

plaque

progression and stability. Cardiovasc Res. 2007;73:470480

40. Mantovani A, Garlanda C, Locati M. Macrophage diversity and polarization in
atherosclerosis: a question of balance. Arteriosclerosis, Thrombosis, and
Vascular Biology. 2009;29(10):14191423
41. Wesemann DR, Benveniste EN. STAT-1 and IFN- as modulators of TNF-
signaling in macrophages: regulation and functional implications of the TNF

receptor 1:STAT-1 complex. Journal of Immunology. 2003;171(10):5313

5319
42. Zhou J, Lhotak S, Hilditch BA, Austin RC. Activation of the unfolded protein
response occurs at all stages of atherosclerotic lesion development in
apolipoprotein E-deficient mice. Circulation. 2005;111:1814 1821
43. Tabas A, Tall, Accili D. The impact of macrophage insulin resistance on
advanced

atherosclerotic

plaque

progression.

Circulation

Research.

2010;106(1):5867
44. Reyes-Escogido
Chemical

M,

and

Gonzalez-Mondragon

Pharmacological

Aspects

EG,
of

Vazquez-Tzompantzi
Capsaicin.

E.

Molecules.

2011;16:1253-1270
45. Ahuja KDK, Robertson IK, Geraghty DP, Ball MJ. Effects of chili
consumption on postprandial glucose, insulin, and energy metabolism. Am J
Clin Nutr. 2006;84:63-9
46. Blanco E, Kessinger CW, Sumer BD, Gao J. Multifunctional Micellar
Nanomedicine for Cancer Therapy. Exp Biol Med. 2009;234(2):123-131
47. Lewis DR, Kamisoglu K, York A, Moghe PV. Polymer-Based Therapeutics:
Nanoassemblies and Nanoparticles for Management of Atherosclerosis. Wiley
Interdiscip Rev Nanomed Nanobiotechnol. 2011;3(4):400-420
48. Chnari E, Nikitczuk JS, Wang J, Uhrich KE, Moghe PV. Engineered Polimeric
Nanoparticles for Receptor-Targeted Blockage of Oxidized Low Density
Lipoprotein Uptake and Atherogenesis in Macrophages. Biomacromolecules.
2006;7:1796-1805
49. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC.
Targeted Polymeric Therapeutic Nanoparticles: Design, Development, and
Clinical Translation. Chem Soc Rev. 2012;41(7):2971-3010
50. Toma A, Otsuji E, Kuriu Y, Okamoto K, Ichikawa D, Hagiwara A, Ito H,
Nishimura T, Yamagishi H. Br. J. Cancer. 2005; 93:131136.
51. Gosk S, Vermehren C, Storm G, Moos T. J. Cereb. Blood Flow Metab. 2004;
24:11931204.

52. Laginha KM, Moase EH, Yu N, Huang A, Allen TM. J. Drug Targeting. 2008;
16:605610.
53. Voinea M, Manduteanu I, Dragomir E, Capraru M, Simionescu M. Pharm. Res.
2005; 22:19061917.
54. Torchilin, Vladimir P. Immunomicelles: Targeted Pharmaceutical Carriers for
Poorly Soluble Drugs. Proceeding of the National Academy of Science. 2003.
55. Kamaly,

et

al.

Targeted

polymeric

therapeutic

nanoparticles:

design,

development, and clinical translation. Chem Soc Rev 2012 41(7):2971-3010.

56. Farokhzad OC, et al. Targeted nanoparticle-aptamer bioconjugates for cancer
chemotherapy in vivo. PNAS 2006;103(16):6315-6320.
57. Jung T, Breitenbach A, Kissel T. J. Controlled Release. 2000;67:157-169
58. Blanco E, Kessinger CW, Sumer BD, and Gao J. Multifunctional Micellar
Nanomedicine for Cancer Therapy. 2009 Exp Biol Med (Maywood)
234(2):123-131.
59. Peters, et al. Targeting atherosclerosis by using modular, multifunctional
micelles. PNAS 2009;106(24):9815-9819.
60. Mourya VK, Inamdar N, Nawale RB, Kulthe SS. Polymeric Micelles: General
Considerations and their Applications. Ind J Pharm Edu Res 2011;45(2):128138.
61. Chorny, M., Fishbein, I., Danenberg, H.D. and Golomb G. Lipophilic drug
loaded nanospheres prepared by nanoprecipitation: effect of formulation
variables on size, drug recovery and release kinetics. J Controlled Release
2002;83:389-400.
62. Chnari E, Jessica SN, Wang J, Uhrich KE, an Moghe PV. Engineered
Polymeric Nanoparticles for Receptor-Targeted Blockage of Oxidized Low
Density

Lipoprotein

Uptake

and

Atherogenesis

in

Macrophages.

Biomacromolecules 2006;7:1756-1805.
63. Sudhakar Johnson, T. and Racishankar, G. A. and Venkataraman, L. V. In vitro
Capsaicin production by immobilized cells and placental tissues of Capsicum
annuum L. grown in liquid medium. Plant Science 1991;70(2):223-229.

64. Escogido M, Edith G, Erika V. Chemical and Pharmacological Aspects of

Capsaicin. Molecules 2011;16:1253-1270.
65. Pandhair V, Sharma S. Accumulation of Capsaicin in Seed, Pericarp and
Placenta of Capsicum annuum L Fruit. Journal of Plant Biochemistry and
Biotechnology 2008;17(1):23-27
66. Arora R, Gill N S, Chauhan G, Rana A C. An Overview about Versatile
Molecule Capsaicin. Int Jour of Pharmaceutical Sciences and Drug Research.
2011. 3(4): 280-286.
67. Noichinda S., Bodhipadma K., Lerksasen P., Ketsa S. Difference in Capsaicin
Content among Thai Capsicum. The Jour App Sci. 2012;11(1):1-4.
68. Pepic et al. Polymeric Micelles in Ocular Drug Delivery: Rationale, Strategies
and Challenges. Chem. Biochem. Eng. Q. 2012. 26(4):365-377.
69. Sakhalkar et al. Enhanced adhesion of ligand-conjugated biodegradable
particles to colitic venules. FASEB J. 2005;19(7):792-4.
70. Gosk, S. VCAM-directed immunoliposomes loaded with vasculardisrupting
agents for selective targeting and occlusion of the tumor vasculature - as a
novel therapeutic strategy. Dissertation Universitaat Bonn. 2007. pp.39-41.
71. Kang DI, Lee S, Lee JT, Sung BJ, Yoon JY, Kim JK, Chung J, Lim SJ.
Preparation

and

in

vitro

evaluation

of

anti-VCAM-1-Fab'-conjugated

liposomes for the targeted delivery of the poorly water-soluble drug celecoxib.
J Microencapsul. 2011. 28(3):220-7.
72. Xu X, Wang P, Zhao Z, Cao T, He H, Luo Z, Zhong J et al. Activation of
transient receptor potential vanilloid 1 by dietary capsaicin delays the onset of
stroke in stroke-prone spontaneously hypertensive rats. AHA Journal. 2011.
42(11):3245-51
73. Mulder WJM, Strijkers GJ, Briley-Saboe KC, Frias JC, Aguinaldo JGS, Vucic
E, Amirbekian V, Tang C, Chin PTK, Nicolay K, Fayad ZA. Molecular
imaging of macrophages in atherosclerotic plaques using bimodal PEGmicelles. Magn Reson Med. 2007. 58(6):11641170.
74. Febbraio M, Sheibani N, Schmitt D, Silverstein R, Hajjar D, Cohen P, et al.
Targeted disruption of the class B scavenger receptor CD36 protects against

atherosclerotic lesion development in mice. J Clin Invest. 2000; 105:10951108.

75. Manning-Tobin JJ, Moore KJ, Seimon TA, Bell SA, Sharuk M, Alvarez-Leite
JI, et al. Loss of SR-A and CD36 activity reduces atherosclerotic lesion
complexity without abrogating foam cell formation in hyperlipidemic mice.
Arterioscler Thromb Vasc Biol. 2009. 29:1926.
76. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endolysosomal escape of poly(DL-lactide-coglycolide) nanoparticles: implications
for drug and gene delivery. FASEB J. 2002;16:12171226.
77. Panyam J, Labasethwar V. Dynamics of Endocytosis and Exocytosis of
Poly(D,L-Lactide-co-Glycolide) Nanoparticles in Vascular Smooth Muscle
Cells. Pharmaceutical Research. 2003;20(2):212-220.
78. SamL, Stephen, Katie F, Sarah D, Michael W, Twigg et al. Scavenger
Receptors and Their Potential as Therapeutic Targets in the Treatment of
Cardiovascular Disease. International Journal of Hypertension. 2010. pp 1-22.
79. Kunjathoor V, Febbraio M, Podrez E, Moore K, Andersson L, Koehn S, et al.
Scavenger receptors class A-I/II and CD36 are the principal receptors
responsible for the uptake of modified low density lipoprotein leading to lipid
loading in macrophages. J Biol Chem. 2002; 277:4998249988.
80. K. C. Thomas, M. Ethirajan, K. Shahrokh et al. Structureactivity relationship
of capsaicin analogs and transient receptor potential vanilloid 1-mediated
human

lung

epithelial

cell toxicity.

Journal

of

Pharmacology

and

Experimental Therapeutics. 2011. vol. 337, no. 2, pp. 400410.

81. Lee

YL,

et

al.

Role

of

TRPV1

in

inflammation-induced

airway

hypersensitivity. Current Opinion in Pharmacology. 2009. vol. 9, no. 3, pp.

243249.
82. Almasi R, Szoke E, Bolcskei K, Varga A, Riedl Z, et al. Actions of 3-methylN-oleoyldopamine and

4-methyl-N-oleoyldopamine

on the rat

receptor in vitro and in vivo. Life Sci. 2008. pp 644651.

TRPV1

83. Zhong B, Wang DH. N-oleoyldopamine, a novel endogenous capsaicinlike

lipid, protects the heart against ischemia-reperfusion injury via activation of
TRPV1. Am J Physiol Heart Circ Physiol. 2008. H728735.
84. Wang H, Wang DH, Galligan JJ. P2Y2 receptors mediate ATP-induced
resensitization of TRPV1 expressed by kidney projecting sensory neurons. Am
J Physiol Regul Integr Comp Physiol. 2010. R16341641.
85. Szallasi A, Cortright DN, Blum CA, Eid SR. The vanilloid receptor TRPV1:
10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug
Discov. 2007. pp 357372.
86. R. Sorrentino, S. Morello, S. Chen, E. Bonavita, and A. Pinto. The activation
of liver X receptors inhibits toll-like receptor-9-induced foam cell formation.
Journal of Cellular Physiology. 2010. vol. 223. no. 1. pp. 158167.
87. L.-C. Cheng, K.-H. Su, Y. R. Kou et al. -Lipoic acid ameliorates foam cell
formation via liver X receptor -dependent upregulation of ATP-binding
cassette transporters A1 and G1. Free Radical Biology andMedicine. 2011. vol.
50, no. 1, pp. 4754.
88. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, and Tontonoz P.
Reciprocal regulation of inflammation and lipid metabolism by liver X
receptors. Nature Medicine. 2003. vol. 9, no. 2, pp. 213219.
89. Bischoff,E.D., Daige,C.L., Petrowski,M., Dedman,H., Pattison,J., Juliano,J.,
Li,A.C. and Schulman,I.G. Non-redundant roles for LXRalpha and LXRbeta
in atherosclerosis susceptibility in low density lipoprotein receptor knockout
mice. J. Lipid Res. 2010.
90. Krasowski,M.D., Ni,A., Hagey,L.R. and Ekins,S. Evolution of promiscuous
nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR. Mol. Cell.
Endocrinol. 2011. 334, 3948.
91. Nedumaran,B., Kim,G.S.,

Hong,S.,

Yoon,Y.-S.,

Kim,Y.-H.,

Lee,C.-H.,

Lee,Y.C., Koo,S.-H. and Choi,H.-S. Orphan nuclear receptor DAX-1 acts as a

novel corepressor of liver X receptor alpha and inhibits hepatic lipogenesis. J.
Biol. Chem. 2010. 285, 92219232.

92. Chinetti GG, Baron M, Bouhlel MA et al. Human Atherosclerotic Plaque

Alternative Macrophages Display Low Cholesterol Handling but High
Phagocytosis Because of Distinct Activities of the PPAR and LXR Pathways.
Circ. Res. 2011. 108, 985995.
93. Jakobsson T, Venteclef N, Toresson G., Damdimopoulos AE., Ehrlund A,
Lou,X, Sanyal,S, Steffensen KR, Gustafsson,JA, and Treuter,E. GPS2 is
required for cholesterol efflux by triggering histone demethylation, LXR
recruitment, and coregulator assembly at the ABCG1 locus. Mol. Cell. 2009.
34, 510518.
94. Laffitte, B.A.

et

al.

LXRs control lipid-inducible expression of the

apolipoprotein E gene in macrophages and adipocytes. Proc. Natl. Acad. Sci.

USA. 2001. 98, 507512.
95. Repa, J.J. et al. Regulation of mouse sterol regulatory element-binding protein1c (SREBP-1c) by oxysterol receptors LXR- and LXR-. Genes Dev. 2000.
14, 28192830.
96. Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ:
Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol
from macrophages to feces in vivo. Circulation. 2003, 108:661-663.
97. Yvan-Charvet, L., Pagler, T.A., Seimon, T.A., Thorp, E., Welch, C.L.,
Witztum, J.L., Tabas, I., and Tall, A.R. ABCA1 and ABCG1 protect against
oxidative stress-induced macrophage apoptosis during efferocytosis. Circ. Res.
2010. 106, 18611869.
98. Groen AK, Bloks VW, Bandsma RH, Ottenhoff R, Chimini G, Kuipers F.
Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking
HDL. J Clin Invest. 2001. 108:843 850.
99. Christopher J. Fielding; and Phoebe E. Fieldins. Molecular physiology of
reverse cholesterol transport. Journal of Lipid Research. Volume 36. 1995. pp
1-18.
100. Wang X, Collins HL, Ranalletta M, Fuki IV, Billheimer JT, Rothblat GH, Tall
AR, Rader DJ: Macrophage ABCA1 and ABCG1, but not SR-BI, promote

macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007.

117:2216-2224.
101. El Bouhassani M, Gilibert S, Moreau M, Saint-Charles F, Treguier M, Poti F,
Chapman MJ, Le Goff W, Lesnik P, Huby T. Cholesteryl ester transfer protein
expression partially attenuates the adverse effects of SR-BI receptor deficiency
on cholesterol metabolism and atherosclerosis. J Biol Chem. 2011, 286:1722717238.
102. Zhang Y, Da Silva JR, Reilly M, Billheimer JT, Rothblat GH, Rader DJ.
Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive
regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest.
2005, 115:2870-2874.
103. Bonizzi G, Karin M. The two NF-kB activation pathways and their role in
innate and adaptive immunity. Trends Immunol 25. 2004. 280288.
104. Chen LW, Egan L, Li ZW, Greten FR, Kagnoff MF, Karin M. The two faces
of IKK and NF-kB inhibition: Prevention of systemic inflammation but
increased local injury following intestinal ischemia-reperfusion. Nat Med 9.
2003. 575581.
105. Correa RG, Matsui T, Tergaonkar V, Rodriguez-Esteban C, Izpisua-Belmonte
JC, Verma IM. Zebrafish IkB kinase 1 negatively regulates NF-kB activity.
Curr Biol 15. 2005. 12911295.
106. Gadjeva M, Tomczak MF, Zhang M, Wang YY, Dull K, Rogers AB, Erdman
SE, Fox JG, Carroll M, Horwitz BH. A role for NF-kB subunits p50 and p65
in the inhibition of lipopolysaccharide-induced shock. J Immunol 173. 2004.
57865793.
107. Mourad Z, Yasuhiro S, Amarjit S. Naura, Chetan P. Hans, Charles Nichols,
and Hamid B. Nuclear Translocation of p65 NF-kB is Sifficient for VCAM-1:
Differential Requirement for PARP-1 Expression and Interaction. Cell Signal.
2008. 20(1): 186-194.
108. Nicole Iverson1, Nicole M. Plourde2, Sarah M. Sparks3 et al. Dual Use of
Amphiphilic Macromolecules As Cholesterol Efflux Triggers and Inhibitors of
Macrophage Athero-inflammation. Biomaterials. 2011. 32(32): 83198327.

109. Liqun M, Jian Z, Zhigang Z et al. Activation of TRPV1 reduces vascular lipid
accumulation and attenuates atherosclerosis. Cardiovascular Research. 2011.
92, 504513
110. Martin T, Tsagogiorgas C, Wedel J, Hottenrott M, Schneider MO, Binzen U,
et al. N-octanoyl-Dopamine Is an Agonist at the Capsaicin Receptor TRPV1
and Mitigates Is Chemia-Induced Acute Kidney Injury in Rat. PLoS ONE.
2012. 7(8): e43525.
111. Lewington S, Whitlock G, Clarke R et al. Blood cholesterol and vascular
mortality by age, sex, and blood pressure: a meta-analysis of individual data
from 61 prospective studies with 55,000 vascular deaths. Lancet 370. 2007.
(9602):182939.
112. Shah PK, et al. Apolipoprotein A-I/HDL infusion therapy for plaque
stabilization-regression:

novel

therapeutic

approach.

Current

Pharmaceutical Design. 2007;13(10):10311038.

113. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B. Safety issues and
prospects for future generations of PPAR modulators. Biochim Biophys Acta.
2007;1771(8):1065-81.
114. Zinn A, Felson S, Fisher E, Schwartzbard A. Reassessing the cardiovascular
risks and benefits of thiazolidindiones. Clinical Cardiology 2008;31(9):397403.
115. Staels B. Fluid retention mediate by renal PPAR-. Cell Metabolism.
2005;2(2):77-78.
116. Jacobsson LT, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T,
Geborek P. Treatment with tumor necrosis factor blockers is associated with a
lower incidence of first cardiovascular events in patients with rheumatoid
arthritis. J Rheumatol. 2005;32:12131218.
117. Emsley HC, Smith CJ, Georgiou RF, Vail A, Hopkins SJ, Rothwell NJ, Tyrrell
PJ. A randomised phase II study of interleukin-1 receptor antagonist in acute
stroke patients. J Neurol Neurosurg Psychiatry. 2005;76:13661372.
118. Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral
infection. Nat Rev Rheumatol. 2010. 6(3):165-74.

119. Prinz JC. Autoimmune-like syndromes during TNF blockade: does infection
have a role?. Nat Rev Rheumatol. 2011. 29;7(7):429-34.
120. Pinto-Alphandary H, Andremont A, Couvreur P. Targeting delivery of
antibiotics using liposomes and nanoparticles: research and applications. Int J
Antimicrob 2000;13:155-168
121. Schuffhan et al. The cost effectiveness of Fluvastatin in Hungary Following
Succesfull PCI. Cardiovasc drugs ther. 2006;13(4):309-317.
122. Jeremy S, Paikin, and John W. Eikelboom. Aspirin. Circulation 2012, 125:e439e442.

123. Ravivarapu HB, Burton K, De Luca PP. Polymer and microsphere blending to
alter the release of a peptide from PLGA microsphere. Eur J Pharm Biopharm
2000. 50:263-70.